Lakefront Biotherapeutics American Depositary Shares
LKFT
52 hedge funds and large institutions have $642M invested in Lakefront Biotherapeutics American Depositary Shares in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 13 closing their positions.
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
21.59% more ownership
Funds ownership: 0% → 21.59% (+22%)
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
8% more funds holding
Funds holding: 48 → 52 (+4)
2% more capital invested
Capital invested by funds: $628M → $642M (+$13.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$18.7M |
| 2 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$8.23M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.6M |
| 4 |
Renaissance Technologies
New York
|
+$4.02M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$10.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.5M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$3.23M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.12M |
| 5 |
Goldman Sachs
New York
|
-$2.79M |
LKFT Hedge Fund Activity: Q4 2016 in Review
52 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2016, worth a combined $642M — up 2.2% from $628M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LKFT positions and 13 closed out — a net gain of 4 holders — while 13 added to existing stakes and 11 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $18.7M. The largest seller was OrbiMed, cutting an estimated $10.7M.
- 52 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2016, up from 48 in Q3 2016.
- Funds reported $642M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2016, up 2.2% quarter-over-quarter.
- 17 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2016 and 13 closed out, a net change of +4 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2016 was Perceptive Advisors, an estimated $18.7M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2016 was OrbiMed, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2016.